RNAi for Therapeutic Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global RNAi for Therapeutic market size was valued at USD 181.1 million in 2022 and is forecast to a readjusted size of USD 2031.2 million by 2029 with a CAGR of 41.2% during review period.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%. US is the largest market, with a share over 75%, followed by EU, which has a share about 3%. In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

This report is a detailed and comprehensive analysis for global RNAi for Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global RNAi for Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for RNAi for Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global RNAi for Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Alnylam Pharmaceuticals
   Arbutus Biopharma (Tekmira)
   Arrowhead
   Dicerna Pharmaceuticals
   Mirna Therapeutics
   Quark Pharmaceuticals
   RXi Pharmaceuticals
   Silence Therapeutics
   Benitec Biopharma
   miRagen Therapeutics
   Sylentis
   Gradalis
   Sirnaomics
   Silenseed

   siRNA
   miRNA
   shRNA

   Cancer
   Cardiovascular
   HBV
   Others

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of RNAi for the therapeutic market in 2025?

RNAi has the potential to precisely target and silence disease-causing genes, offering a highly specific approach for treating genetic disorders and cancers. Advances in delivery mechanisms, such as lipid nanoparticles, are making RNAi more effective and less toxic, increasing its potential as a viable treatment option.

What are the weaknesses of RNAi for the therapeutic market in 2025?

One of the main weaknesses is the challenge of efficiently delivering RNAi molecules to specific cells or tissues without causing immune reactions. Additionally, the long-term safety and stability of RNAi therapies remain uncertain, and the high cost of development could limit accessibility.

What are the opportunities for RNAi in the therapeutic market in 2025?

With the growing focus on personalized medicine, RNAi offers the opportunity to develop highly individualized treatments targeting rare genetic diseases. Additionally, expanding applications for cancer, neurological conditions, and viral infections provide significant growth potential in the therapeutic market.

What are the threats to RNAi in the therapeutic market in 2025?

The threat of competition from other gene-editing technologies like CRISPR could overshadow RNAi-based therapies. Moreover, regulatory hurdles, long development timelines, and the risk of off-target effects or unintended consequences could slow down the widespread adoption of RNAi therapies.

What are the political factors influencing RNAi for the therapeutic market in 2025?

Government regulations and funding play a crucial role in the development of RNAi therapies. Political support for healthcare innovation and gene-based therapies could accelerate research and development, while shifting policies or regulatory uncertainty could delay approvals and affect market entry.

How do economic factors impact RNAi for the therapeutic market in 2025?

The high cost of developing RNAi-based therapies may limit accessibility, especially in low- and middle-income countries. However, as the market matures and competition increases, economies of scale could drive down costs. Additionally, reimbursement policies and healthcare spending priorities will directly affect market growth.

What social factors are affecting RNAi for the therapeutic market in 2025?

There is a growing awareness and demand for personalized medicine, which could lead to increased acceptance of RNAi therapies, especially for rare and genetic diseases. However, societal concerns about gene-editing technologies and ethical issues surrounding RNAi treatments may slow adoption and acceptance among certain groups.

What technological factors are influencing RNAi for the therapeutic market in 2025?

Advances in nanotechnology and delivery systems, such as lipid nanoparticles, are enhancing the effectiveness of RNAi therapies. Innovations in genome sequencing and data analytics also enable more precise targeting of specific genes. However, challenges remain in perfecting RNAi delivery and ensuring safety and efficacy at the cellular level.

What environmental factors impact RNAi for the therapeutic market in 2025?

Environmental concerns related to the production and disposal of RNAi therapies, such as potential pollution from manufacturing processes, could face increasing scrutiny. Additionally, eco-friendly production methods and sustainability initiatives may influence the development and approval of RNAi treatments.

What legal factors affect RNAi for the therapeutic market in 2025?

Intellectual property rights, patents, and licensing agreements are crucial in determining the competitive landscape for RNAi therapies. Legal challenges related to patent disputes, as well as regulatory frameworks governing gene-based therapies, will shape how quickly RNAi treatments can reach the market and be widely adopted.

Who are the suppliers in the RNAi for therapeutic market in 2025?

Suppliers include biotechnology companies specializing in RNAi research, pharmaceutical manufacturers, and firms providing delivery systems such as lipid nanoparticles or viral vectors. Additionally, suppliers of raw materials for RNA synthesis and gene-editing tools also play a crucial role.

What are the inputs for RNAi-based therapeutics in the market?

Inputs include RNAi molecules (siRNA or shRNA), gene sequencing data for precise targeting, advanced delivery systems, clinical trial data, and regulatory approvals. These inputs are essential for the development of effective and safe RNAi therapies.

What are the processes involved in RNAi-based therapeutics development?

The key processes include research and development, molecular synthesis, preclinical studies, clinical trials, and regulatory review. The manufacturing process for RNAi therapeutics also includes scaling up RNA production, ensuring quality control, and optimizing delivery methods for targeted therapy.

What are the outputs of RNAi for the therapeutic market in 2025?

The outputs are RNAi-based therapeutic products aimed at treating genetic disorders, cancers, viral infections, and other conditions that require gene silencing. These include FDA-approved drugs, clinical trial results, and commercially available treatments.

Who are the customers for RNAi-based therapeutics in the market?

Customers include healthcare providers, hospitals, research institutions, and patients, particularly those with rare genetic diseases or cancers. Pharmaceutical companies also act as customers for RNAi technologies, as they integrate these innovations into their treatment portfolios.

What is the threat of new entrants in the RNAi for therapeutic market in 2025?

The threat of new entrants is moderate. While the market presents high growth potential, the complexity and high costs of developing RNAi-based therapies, along with regulatory hurdles, create barriers to entry. Established companies with the necessary resources and expertise dominate the market.

What is the bargaining power of suppliers in the RNAi for therapeutic market in 2025?

The bargaining power of suppliers is moderate to high. Suppliers of raw materials for RNA synthesis, advanced delivery systems, and gene-editing technologies play a crucial role in the development of RNAi therapies. As the market grows, suppliers will have more influence, especially if specialized components are needed.

What is the bargaining power of buyers in the RNAi for therapeutic market in 2025?

The bargaining power of buyers is low. RNAi therapies are often aimed at treating rare genetic diseases and cancers, where there are limited treatment options. As a result, buyers, particularly healthcare providers and patients, have fewer alternatives, which gives companies more pricing power.

What is the threat of substitute products or services in the RNAi for therapeutic market in 2025?

The threat of substitutes is moderate. While RNAi holds significant potential for gene therapy, other emerging technologies like CRISPR and gene-editing tools present competitive alternatives. Additionally, conventional drug therapies may still be used in cases where RNAi treatments are not viable.

What is the intensity of competitive rivalry in the RNAi for therapeutic market in 2025?

The intensity of competitive rivalry is moderate to high. The market is becoming increasingly competitive as several biotechnology and pharmaceutical companies invest in RNAi-based therapies. The race to develop safe and effective therapies, along with patent protection and regulatory approvals, creates a dynamic and competitive landscape.

What are the key inputs for RNAi-based therapeutic development in 2025?

The key inputs include RNA molecules (siRNA, shRNA), advanced gene sequencing data for precise targeting, specialized delivery systems (such as lipid nanoparticles and viral vectors), research materials, and skilled labor for molecular biology techniques.

What are the major suppliers involved in the upstream process of RNAi for therapeutic market in 2025?

Major suppliers include biotechnology firms providing RNA synthesis technologies, suppliers of delivery system technologies, research institutions for developing gene-editing tools, and companies that manufacture raw materials used in the development of RNAi molecules and therapeutics.

What are the technological advancements influencing the upstream processes in RNAi-based therapies?

Technological advancements such as improved RNA synthesis methods, more efficient delivery systems (e.g., nanoparticles), and enhanced genome sequencing technologies are crucial. These developments are enabling better targeting of diseases and improving the effectiveness of RNAi therapeutics.

What are the regulatory challenges affecting the upstream process for RNAi-based therapeutics?

Regulatory challenges include the approval processes for new RNAi-based therapies, safety and efficacy assessments, and compliance with manufacturing standards. Regulatory agencies require extensive preclinical and clinical trial data to ensure that RNAi therapies are safe and effective for human use.

How does the cost structure impact the upstream activities in RNAi-based therapeutic development?

The high cost of developing RNAi-based therapeutics, especially in terms of research, production, and clinical trials, impacts the upstream process significantly. Companies must secure substantial funding and partnerships to cover these costs, which could influence the development pace and scalability of therapies.

What are the key activities involved in the midstream process of RNAi-based therapeutics in 2025?

The key activities in the midstream process include the optimization of RNAi formulations, the development of effective delivery systems, clinical trials to test safety and efficacy, and refining the manufacturing processes for large-scale production of RNAi-based therapies.

What are the major challenges faced during the midstream phase of RNAi therapeutic development?

Major challenges include ensuring the stability and efficacy of RNAi molecules in the body, overcoming delivery barriers to target specific tissues, managing potential immune responses, and adhering to strict regulatory requirements during clinical trials.

How does the clinical trial process impact the midstream activities for RNAi therapies?

The clinical trial process is crucial in validating the safety and effectiveness of RNAi therapies. Delays in trial recruitment, safety concerns, and regulatory hurdles can slow down the progress of midstream activities, impacting the overall timeline for market entry.

What role do partnerships and collaborations play in the midstream development of RNAi therapeutics?

Partnerships with academic institutions, biotechnology companies, and contract manufacturing organizations are critical in the midstream phase. These collaborations help with expertise in delivery technologies, scale-up production, and regulatory navigation, accelerating the development of RNAi therapies.

What are the cost-related factors impacting the midstream phase of RNAi-based therapeutics?

The cost of clinical trials, manufacturing scale-up, and the need for specialized equipment and facilities add significant financial pressure in the midstream phase. Companies must secure adequate funding to cover these high costs and ensure the continued development and testing of RNAi therapies.

What are the key activities involved in the downstream process of RNAi-based therapeutics in 2025?

The key activities include commercialization, distribution, post-market surveillance, and patient education. After approval, RNAi therapies need to be marketed, distributed through healthcare providers, and monitored for long-term safety and effectiveness in real-world applications.

What are the challenges faced during the downstream phase of RNAi therapeutic development?

Challenges include ensuring widespread access to RNAi therapies, dealing with the high cost of treatment, managing reimbursement and insurance coverage issues, and addressing potential long-term safety concerns that arise post-approval.

How do market adoption and acceptance affect the downstream process of RNAi-based therapeutics?

Market adoption is crucial for the success of RNAi therapies. Physicians and patients need to be educated on the benefits and risks, and widespread acceptance depends on proven efficacy, safety, and affordability. Negative perceptions or hesitation regarding gene therapies could slow down adoption.

What role do distribution channels play in the downstream activities for RNAi-based therapies?

Efficient distribution channels are essential for ensuring that RNAi therapies reach the right healthcare providers and patients. These channels include hospitals, clinics, specialty pharmacies, and direct-to-patient services. Proper logistics and a reliable supply chain are critical to maintaining therapy availability.

How does post-market surveillance impact the downstream process of RNAi therapies?

Post-market surveillance is essential for monitoring the real-world safety and efficacy of RNAi therapies. Continuous tracking and reporting of adverse events help refine treatment protocols and ensure that therapies are providing the expected outcomes, which builds trust and enhances market sustainability.

Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2018 to 2023.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNAi for Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi for Therapeutic.
Chapter 13, to describe RNAi for Therapeutic research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of RNAi for Therapeutic
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of RNAi for Therapeutic by Type
       1.3.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global RNAi for Therapeutic Consumption Value Market Share by Type in 2022
       1.3.3 siRNA
       1.3.4 miRNA
       1.3.5 shRNA
   1.4 Global RNAi for Therapeutic Market by Application
       1.4.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Cancer
       1.4.3 Cardiovascular
       1.4.4 HBV
       1.4.5 Others
   1.5 Global RNAi for Therapeutic Market Size & Forecast
   1.6 Global RNAi for Therapeutic Market Size and Forecast by Region
       1.6.1 Global RNAi for Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global RNAi for Therapeutic Market Size by Region, (2018-2029)
       1.6.3 North America RNAi for Therapeutic Market Size and Prospect (2018-2029)
       1.6.4 Europe RNAi for Therapeutic Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2018-2029)
       1.6.6 South America RNAi for Therapeutic Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Alnylam Pharmaceuticals
       2.1.1 Alnylam Pharmaceuticals Details
       2.1.2 Alnylam Pharmaceuticals Major Business
       2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
       2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
   2.2 Arbutus Biopharma (Tekmira)
       2.2.1 Arbutus Biopharma (Tekmira) Details
       2.2.2 Arbutus Biopharma (Tekmira) Major Business
       2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
       2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
   2.3 Arrowhead
       2.3.1 Arrowhead Details
       2.3.2 Arrowhead Major Business
       2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
       2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Arrowhead Recent Developments and Future Plans
   2.4 Dicerna Pharmaceuticals
       2.4.1 Dicerna Pharmaceuticals Details
       2.4.2 Dicerna Pharmaceuticals Major Business
       2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
       2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
   2.5 Mirna Therapeutics
       2.5.1 Mirna Therapeutics Details
       2.5.2 Mirna Therapeutics Major Business
       2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
       2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Mirna Therapeutics Recent Developments and Future Plans
   2.6 Quark Pharmaceuticals
       2.6.1 Quark Pharmaceuticals Details
       2.6.2 Quark Pharmaceuticals Major Business
       2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
       2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
   2.7 RXi Pharmaceuticals
       2.7.1 RXi Pharmaceuticals Details
       2.7.2 RXi Pharmaceuticals Major Business
       2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
       2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
   2.8 Silence Therapeutics
       2.8.1 Silence Therapeutics Details
       2.8.2 Silence Therapeutics Major Business
       2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
       2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Silence Therapeutics Recent Developments and Future Plans
   2.9 Benitec Biopharma
       2.9.1 Benitec Biopharma Details
       2.9.2 Benitec Biopharma Major Business
       2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
       2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 Benitec Biopharma Recent Developments and Future Plans
   2.10 miRagen Therapeutics 
       2.10.1 miRagen Therapeutics Details
       2.10.2 miRagen Therapeutics Major Business
       2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
       2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 miRagen Therapeutics Recent Developments and Future Plans
   2.11 Sylentis
       2.11.1 Sylentis Details
       2.11.2 Sylentis Major Business
       2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
       2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 Sylentis Recent Developments and Future Plans
   2.12 Gradalis
       2.12.1 Gradalis Details
       2.12.2 Gradalis Major Business
       2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
       2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 Gradalis Recent Developments and Future Plans
   2.13 Sirnaomics
       2.13.1 Sirnaomics Details
       2.13.2 Sirnaomics Major Business
       2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
       2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 Sirnaomics Recent Developments and Future Plans
   2.14 Silenseed
       2.14.1 Silenseed Details
       2.14.2 Silenseed Major Business
       2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
       2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
       2.14.5 Silenseed Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global RNAi for Therapeutic Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of RNAi for Therapeutic by Company Revenue
       3.2.2 Top 3 RNAi for Therapeutic Players Market Share in 2022
       3.2.3 Top 6 RNAi for Therapeutic Players Market Share in 2022
   3.3 RNAi for Therapeutic Market: Overall Company Footprint Analysis
       3.3.1 RNAi for Therapeutic Market: Region Footprint
       3.3.2 RNAi for Therapeutic Market: Company Product Type Footprint
       3.3.3 RNAi for Therapeutic Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global RNAi for Therapeutic Consumption Value and Market Share by Type (2018-2023)
   4.2 Global RNAi for Therapeutic Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global RNAi for Therapeutic Consumption Value Market Share by Application (2018-2023)
   5.2 Global RNAi for Therapeutic Market Forecast by Application (2024-2029)

6 North America

   6.1 North America RNAi for Therapeutic Consumption Value by Type (2018-2029)
   6.2 North America RNAi for Therapeutic Consumption Value by Application (2018-2029)
   6.3 North America RNAi for Therapeutic Market Size by Country
       6.3.1 North America RNAi for Therapeutic Consumption Value by Country (2018-2029)
       6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2018-2029)
       6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2018-2029)
       6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe RNAi for Therapeutic Consumption Value by Type (2018-2029)
   7.2 Europe RNAi for Therapeutic Consumption Value by Application (2018-2029)
   7.3 Europe RNAi for Therapeutic Market Size by Country
       7.3.1 Europe RNAi for Therapeutic Consumption Value by Country (2018-2029)
       7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2018-2029)
       7.3.3 France RNAi for Therapeutic Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2018-2029)
       7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2018-2029)
       7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
       8.3.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2018-2029)
       8.3.2 China RNAi for Therapeutic Market Size and Forecast (2018-2029)
       8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2018-2029)
       8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2018-2029)
       8.3.5 India RNAi for Therapeutic Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2018-2029)
       8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2018-2029)

9 South America

   9.1 South America RNAi for Therapeutic Consumption Value by Type (2018-2029)
   9.2 South America RNAi for Therapeutic Consumption Value by Application (2018-2029)
   9.3 South America RNAi for Therapeutic Market Size by Country
       9.3.1 South America RNAi for Therapeutic Consumption Value by Country (2018-2029)
       9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2018-2029)
       9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
       10.3.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2018-2029)
       10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2018-2029)
       10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 RNAi for Therapeutic Market Drivers
   11.2 RNAi for Therapeutic Market Restraints
   11.3 RNAi for Therapeutic Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 RNAi for Therapeutic Industry Chain
   12.2 RNAi for Therapeutic Upstream Analysis
   12.3 RNAi for Therapeutic Midstream Analysis
   12.4 RNAi for Therapeutic Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global RNAi for Therapeutic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global RNAi for Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global RNAi for Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 6. Alnylam Pharmaceuticals Major Business
   Table 7. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
   Table 8. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Alnylam Pharmaceuticals Recent Developments and Future Plans
   Table 10. Arbutus Biopharma (Tekmira) Company Information, Head Office, and Major Competitors
   Table 11. Arbutus Biopharma (Tekmira) Major Business
   Table 12. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
   Table 13. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
   Table 15. Arrowhead Company Information, Head Office, and Major Competitors
   Table 16. Arrowhead Major Business
   Table 17. Arrowhead RNAi for Therapeutic Product and Solutions
   Table 18. Arrowhead RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Arrowhead Recent Developments and Future Plans
   Table 20. Dicerna Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 21. Dicerna Pharmaceuticals Major Business
   Table 22. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
   Table 23. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Dicerna Pharmaceuticals Recent Developments and Future Plans
   Table 25. Mirna Therapeutics Company Information, Head Office, and Major Competitors
   Table 26. Mirna Therapeutics Major Business
   Table 27. Mirna Therapeutics RNAi for Therapeutic Product and Solutions
   Table 28. Mirna Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Mirna Therapeutics Recent Developments and Future Plans
   Table 30. Quark Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 31. Quark Pharmaceuticals Major Business
   Table 32. Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
   Table 33. Quark Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Quark Pharmaceuticals Recent Developments and Future Plans
   Table 35. RXi Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 36. RXi Pharmaceuticals Major Business
   Table 37. RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
   Table 38. RXi Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. RXi Pharmaceuticals Recent Developments and Future Plans
   Table 40. Silence Therapeutics Company Information, Head Office, and Major Competitors
   Table 41. Silence Therapeutics Major Business
   Table 42. Silence Therapeutics RNAi for Therapeutic Product and Solutions
   Table 43. Silence Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. Silence Therapeutics Recent Developments and Future Plans
   Table 45. Benitec Biopharma Company Information, Head Office, and Major Competitors
   Table 46. Benitec Biopharma Major Business
   Table 47. Benitec Biopharma RNAi for Therapeutic Product and Solutions
   Table 48. Benitec Biopharma RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 49. Benitec Biopharma Recent Developments and Future Plans
   Table 50. miRagen Therapeutics Company Information, Head Office, and Major Competitors
   Table 51. miRagen Therapeutics Major Business
   Table 52. miRagen Therapeutics RNAi for Therapeutic Product and Solutions
   Table 53. miRagen Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 54. miRagen Therapeutics Recent Developments and Future Plans
   Table 55. Sylentis Company Information, Head Office, and Major Competitors
   Table 56. Sylentis Major Business
   Table 57. Sylentis RNAi for Therapeutic Product and Solutions
   Table 58. Sylentis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 59. Sylentis Recent Developments and Future Plans
   Table 60. Gradalis Company Information, Head Office, and Major Competitors
   Table 61. Gradalis Major Business
   Table 62. Gradalis RNAi for Therapeutic Product and Solutions
   Table 63. Gradalis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 64. Gradalis Recent Developments and Future Plans
   Table 65. Sirnaomics Company Information, Head Office, and Major Competitors
   Table 66. Sirnaomics Major Business
   Table 67. Sirnaomics RNAi for Therapeutic Product and Solutions
   Table 68. Sirnaomics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 69. Sirnaomics Recent Developments and Future Plans
   Table 70. Silenseed Company Information, Head Office, and Major Competitors
   Table 71. Silenseed Major Business
   Table 72. Silenseed RNAi for Therapeutic Product and Solutions
   Table 73. Silenseed RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 74. Silenseed Recent Developments and Future Plans
   Table 75. Global RNAi for Therapeutic Revenue (USD Million) by Players (2018-2023)
   Table 76. Global RNAi for Therapeutic Revenue Share by Players (2018-2023)
   Table 77. Breakdown of RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 78. Market Position of Players in RNAi for Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 79. Head Office of Key RNAi for Therapeutic Players
   Table 80. RNAi for Therapeutic Market: Company Product Type Footprint
   Table 81. RNAi for Therapeutic Market: Company Product Application Footprint
   Table 82. RNAi for Therapeutic New Market Entrants and Barriers to Market Entry
   Table 83. RNAi for Therapeutic Mergers, Acquisition, Agreements, and Collaborations
   Table 84. Global RNAi for Therapeutic Consumption Value (USD Million) by Type (2018-2023)
   Table 85. Global RNAi for Therapeutic Consumption Value Share by Type (2018-2023)
   Table 86. Global RNAi for Therapeutic Consumption Value Forecast by Type (2024-2029)
   Table 87. Global RNAi for Therapeutic Consumption Value by Application (2018-2023)
   Table 88. Global RNAi for Therapeutic Consumption Value Forecast by Application (2024-2029)
   Table 89. North America RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
   Table 90. North America RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
   Table 91. North America RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
   Table 92. North America RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
   Table 93. North America RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
   Table 94. North America RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
   Table 95. Europe RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
   Table 96. Europe RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
   Table 97. Europe RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
   Table 98. Europe RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
   Table 99. Europe RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
   Table 100. Europe RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
   Table 101. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
   Table 102. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
   Table 103. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
   Table 104. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
   Table 105. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
   Table 106. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
   Table 107. South America RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
   Table 108. South America RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
   Table 109. South America RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
   Table 110. South America RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
   Table 111. South America RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
   Table 112. South America RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
   Table 113. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
   Table 114. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
   Table 115. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
   Table 116. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
   Table 117. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
   Table 118. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
   Table 119. RNAi for Therapeutic Raw Material
   Table 120. Key Suppliers of RNAi for Therapeutic Raw Materials

List of Figures

   Figure 1. RNAi for Therapeutic Picture
   Figure 2. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global RNAi for Therapeutic Consumption Value Market Share by Type in 2022
   Figure 4. siRNA
   Figure 5. miRNA
   Figure 6. shRNA
   Figure 7. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 8. RNAi for Therapeutic Consumption Value Market Share by Application in 2022
   Figure 9. Cancer Picture
   Figure 10. Cardiovascular Picture
   Figure 11. HBV Picture
   Figure 12. Others Picture
   Figure 13. Global RNAi for Therapeutic Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 14. Global RNAi for Therapeutic Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 15. Global Market RNAi for Therapeutic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 16. Global RNAi for Therapeutic Consumption Value Market Share by Region (2018-2029)
   Figure 17. Global RNAi for Therapeutic Consumption Value Market Share by Region in 2022
   Figure 18. North America RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 19. Europe RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 20. Asia-Pacific RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 21. South America RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 22. Middle East and Africa RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 23. Global RNAi for Therapeutic Revenue Share by Players in 2022
   Figure 24. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 25. Global Top 3 Players RNAi for Therapeutic Market Share in 2022
   Figure 26. Global Top 6 Players RNAi for Therapeutic Market Share in 2022
   Figure 27. Global RNAi for Therapeutic Consumption Value Share by Type (2018-2023)
   Figure 28. Global RNAi for Therapeutic Market Share Forecast by Type (2024-2029)
   Figure 29. Global RNAi for Therapeutic Consumption Value Share by Application (2018-2023)
   Figure 30. Global RNAi for Therapeutic Market Share Forecast by Application (2024-2029)
   Figure 31. North America RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
   Figure 32. North America RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
   Figure 33. North America RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
   Figure 34. United States RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 35. Canada RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 36. Mexico RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 37. Europe RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
   Figure 38. Europe RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
   Figure 39. Europe RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
   Figure 40. Germany RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 41. France RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 42. United Kingdom RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 43. Russia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 44. Italy RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 45. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
   Figure 46. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
   Figure 47. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Region (2018-2029)
   Figure 48. China RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 49. Japan RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 50. South Korea RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 51. India RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 52. Southeast Asia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 53. Australia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 54. South America RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
   Figure 55. South America RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
   Figure 56. South America RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
   Figure 57. Brazil RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 58. Argentina RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 59. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
   Figure 60. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
   Figure 61. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
   Figure 62. Turkey RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 63. Saudi Arabia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 64. UAE RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
   Figure 65. RNAi for Therapeutic Market Drivers
   Figure 66. RNAi for Therapeutic Market Restraints
   Figure 67. RNAi for Therapeutic Market Trends
   Figure 68. Porters Five Forces Analysis
   Figure 69. Manufacturing Cost Structure Analysis of RNAi for Therapeutic in 2022
   Figure 70. Manufacturing Process Analysis of RNAi for Therapeutic
   Figure 71. RNAi for Therapeutic Industrial Chain
   Figure 72. Methodology
   Figure 73. Research Process and Data Source